-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 29th, Betta Pharmaceuticals announced that it received the "Notice of Acceptance" issued by the NMPA, and the company declared BPI-23314 tablets for the treatment of malignant hematological tumors (including but not limited to myelofibrosis and other myeloproliferative tumors and myelodysplastic syndromes.
BPI-23314 is a new molecular entity with completely independent intellectual property rights independently developed by Betta Pharmaceuticals.